# US 2014/0193443 A1 · Method of treating cancer with an hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0193443 A1
- Document ID: US20140193443A1
- Status: Published application
- Kind: A1
- Application number: 14/145,363
- Filed: 2013-12-31
- Published: 2014-07-10
- Earliest claimed: 2006-02-22
- Assignees: International Institute of Cancer Immunology, Inc.
- Applicants: International Institute of Cancer Immunology, Inc.
- Inventors: Haruo SUGIYAMA
- Web page: https://patentgrep.com/patent/US20140193443A1

## CPC

- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4243: {Wilms tumor 1 [WT1]}
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- G01N 33/505: {involving T-cells}
- G01N 33/575: for cancer
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and a method of treating cancer using the peptide.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A method for the treatment of cancer in an HLA-A*3303 positive subject, comprising administering to the subject a peptide comprising Thr Ser Glu Lys Pro Phe Ser Cys Arg (SEQ ID No: 5).

### Claim 22 (depends on 21)

The method according to claim 21, wherein the peptide binds to an HLA-A*3303 molecule.

### Claim 23 (depends on 21)

The method according to claim 21, wherein the peptide induces a WT1-specific CTL in the subject.

### Claim 24 (depends on 21)

The method according to claim 21, further comprising administering to the subject an adjuvant with the peptide.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the adjuvant is selected from a complete Freund's adjuvant, an incomplete Freund's adjuvant, and aluminum hydroxide.

### Claim 26 (depends on 21)

The method according to claim 21, wherein the cancer is selected from leukemia, myelodysplastic syndrome, multiple myeloma, malignant lymphoma, gastric cancer, colon cancer, lung cancer, breast cancer, germ cell cancer, hepatic cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical cancer and ovarian cancer.

### Claim 27

A method for the treatment of cancer in an HLA-A*3303 positive subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a peptide comprising Thr Ser Glu Lys Pro Phe Ser Cys Arg (SEQ ID No: 5).

### Claim 28 (depends on 27)

The method according to claim 27, wherein the peptide binds to an HLA-A*3303 molecule.

### Claim 29 (depends on 27)

The method according to claim 27, wherein the peptide induces a WT1-specific CTL in the subject.

### Claim 30 (depends on 27)

The method according to claim 27, wherein the pharmaceutical composition further comprises at least one second component.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the at least one second component is an adjuvant.

### Claim 32 (depends on 31)

The method according to claim 31, wherein the adjuvant is selected from a complete Freund's adjuvant, an incomplete Freund's adjuvant, and aluminum hydroxide.

### Claim 33 (depends on 27)

The method according to claim 27, further comprising administering to the subject a second agent with the pharmaceutical composition.

### Claim 34 (depends on 33)

The method according to claim 33, wherein the second agent is an adjuvant.

### Claim 35 (depends on 34)

The method according to claim 34, wherein the adjuvant is selected from a complete Freund's adjuvant, an incomplete Freund's adjuvant, and aluminum hydroxide.

### Claim 36 (depends on 27)

The method according to claim 27, wherein the cancer is selected from leukemia, myelodysplastic syndrome, multiple myeloma, malignant lymphoma, gastric cancer, colon cancer, lung cancer, breast cancer, germ cell cancer, hepatic cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical cancer and ovarian cancer.